Business Context and Reporting Period
Company: Cardiff Oncology, Inc. (CRDF)
Filing Type: Form 8-K (Current Report)
Date of Report: November 18, 2021
Event Date: November 17, 2021
Context: The Company entered into a Material Definitive Agreement involving a registered direct offering of common stock and an Information Rights Agreement.
Key Financial Metrics
Capital Raise: Approximately $15.0 million in aggregate gross proceeds.
Shares Issued: 2,411,575 shares of Common Stock.
Price Per Share: $6.22.
Investor: Pfizer Inc.
Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity as this is a transaction report rather than a periodic financial statement.
Material Changes and Transaction Details
- Securities Purchase Agreement: Cardiff Oncology agreed to sell shares to Pfizer in a registered direct offering. The closing is subject to customary conditions.
- Lock-Up Period: Pfizer has agreed not to sell or transfer the Common Shares for 180 days from the closing date, subject to customary exceptions.
- Information Rights Agreement: Pfizer secured rights to access pre-clinical or final clinical data regarding the onvansertib development program. Cardiff must provide this data to Pfizer at least two business days prior to sharing it with any third party. This agreement is effective until May 17, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing focuses on the execution of the capital raise and the strategic partnership with Pfizer regarding data access for the onvansertib program. No specific financial guidance or outlook for future periods is provided in this document.
Risks and Contingencies: The closing of the offering is contingent upon the satisfaction of specified customary closing conditions. The filing includes standard disclaimers regarding the legality of the offer in various jurisdictions.
Key Facts for Investor Verification
- Verify the closing date and final net proceeds after deducting offering expenses.
- Confirm the dilution impact of the 2,411,575 new shares on existing shareholders.
- Monitor the 180-day lock-up expiration for Pfizer to assess potential future selling pressure.
- Track the onvansertib development program milestones, as Pfizer has prioritized data access rights.
- Review the definitive Purchase Agreement (Exhibit 10.1) for specific closing conditions and representations.